Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.
Biomarker testing is having growing importance to ensure that patients are started on the correct therapy for the best outcomes, said Sneha Sharma, PharmD, director, specialty clinical solutions, Magellan Rx.
Transcript
What role might genetic testing or the increasing number of approved companion diagnostics play to manage the escalating costs of oncology therapies?
So, genetic or biomarker testing is going to be critical moving forward, not only to manage costs—because we want to make sure that the patient is on the correct therapy, what their tumor mutations and their tumor looks like—it's also going to help for positive outcomes, which should also give us the correct duration of therapy, reduce side effects, and manage those types of adverse events that patients might have experienced otherwise that could defer them out of therapy because they were started on the wrong drug.
How are biosimilars currently fitting into strategies to manage costs in areas where biosimilars are approved?
Biosimilars are a great alternative to where we have brand name products or generic products to those. We're seeing biosimilar, or biobetter, strategies as a step through strategy. We're seeing biosimilars to be used first line, before we get to other drugs within the class. And the number of biosimilars that are getting approved yearly is great to see and have alternatives in care.
Oncology Onward: A Conversation With Thyme Care CEO and Cofounder Robin Shah
October 2nd 2023Robin Shah, CEO of Thyme Care, which he founded in 2020 with Bobby Green, MD, president and chief medical officer, joins hosts Emeline Aviki, MD, MBA, and Stephen Schleicher, MD, MBA, to discuss his evolution as an entrepreneur in oncology care innovation and his goal of positively changing how patients experience the cancer system.
Listen
Disease-Modifying Antirheumatic Drugs Linked to Decreased Risk for Autoimmune Thyroid Disease
November 28th 2023A nationwide cohort study linked biologic disease-modifying antirheumatic drugs with decreased risks for the onset of autoimmune thyroid disease in patients with rheumatoid arthritis.
Read More
Nathan Walcker Discusses Value-Based Oncology Care Initiatives at FCS
September 8th 2023Nathan Walcker, CEO at Florida Cancer Specialists & Research Institute (FCS), highlights some of the recent partnerships and initiatives at FCS to improve community-based oncology care from a value-based perspective.
Listen
Network Meta-Analysis Validates the Use of Methotrexate in RA Compared With Other Treatments
November 24th 2023A network meta-analysis confirmed the efficacy of methotrexate for patients with rheumatoid arthritis (RA) and validated it as the primary reference conventional synthetic disease-modifying antirheumatic drug for treatment in this population.
Read More